Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

344282 Forskolin, Coleus forskohlii in DMSO - Calbiochem

344282
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Tabla espec. clave

Empirical Formula
C₂₂H₃₄O₇

Products

Número de referenciaEmbalaje Cant./Env.
344282-5MG Frasco de vidrio 5 mg
Description
OverviewThe major cell-permeable diterpene isolated from the Indian plant Coleus forskohlii. At low doses, it acts as a positive inotropic agent. At higher doses, it serves as a hypotensive and vasodilatory agent due to its actions as a smooth muscle relaxant. No major side effects are observed at effective doses. Forskolins pharmacological activities are due to its activation of adenylate cyclase (EC50 = 4 µM), resulting in increased cAMP levels. The exact mechanism of forskolins positive inotropic effect is unknown but may be related to a cAMP-dependent increase in Na+ permeability that results in indirect augmentation of Ca2+ release. Inhibits MAP kinase in rat renal mesangial cells (IC50 = 25 µM). Also acts as a Hh pathway antagonist. Shown to inhibit apoptosis in cerebellar granule cells and to induce apoptosis in resting human B lymphocytes. The solid form of this compound (Cat. No. 344270) is also available.
Catalogue Number344282
Brand Family Calbiochem®
References
ReferencesD'Orazio, J.A., et al. 2006. Nature 443, 340.
Noveen, A., et al. 1996. Biochem. Biophys. Res. Commun. 219, 180.
Galli, C., et al. 1995. J. Neurosci. 15, 1172.
Li, X., et al. 1995. Am. J. Physiol. 269, C986.
Lomo, J., et al. 1995. J. Immunol. 154, 1634.
Uneyama, H., et al. 1993. J. Biol. Chem. 268, 168.
Laurenza, A., et al. 1989. Trends Pharmacol. Sci. 10, 442.
Adashi, E.Y., and Resnick, C.E. 1986. J. Cell. Biochem. 31, 217.
Seamon, K.B., and Daly, J.W. 1986. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 20, 1.
Huang, R., et al. 1982. Cyclic Nucleotide Res. 8, 385.
Metzger, H., and Lindner, E. 1981. IRCS Med. Sci. Biochem. Cardiovasc. System Pharmacol. 9, 99.
Product Information
FormLiquid
FormulationA 50 mM (5 mg/244 µl) solution of Forskolin, Coleus forskohlii (Cat. No. 344270) in DMSO.
Hill FormulaC₂₂H₃₄O₇
Chemical formulaC₂₂H₃₄O₇
Hygroscopic Hygroscopic
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Purity≥97% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
R PhraseR: 36/38

Irritating to eyes and skin.
S PhraseS: 26-36-45

In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
Wear suitable protective clothing.
In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
Product Usage Statements
Storage and Shipping Information
Ship Code Dry Ice Only
Toxicity Irritant
Storage -20°C
Protect from Light Protect from light
Hygroscopic Hygroscopic
Do not freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
344282-5MG 04055977214680

Documentation

Forskolin, Coleus forskohlii in DMSO - Calbiochem Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Forskolin, Coleus forskohlii in DMSO - Calbiochem Certificados de análisis

CargoNúmero de lote
344282

Referencias bibliográficas

Visión general referencias
D'Orazio, J.A., et al. 2006. Nature 443, 340.
Noveen, A., et al. 1996. Biochem. Biophys. Res. Commun. 219, 180.
Galli, C., et al. 1995. J. Neurosci. 15, 1172.
Li, X., et al. 1995. Am. J. Physiol. 269, C986.
Lomo, J., et al. 1995. J. Immunol. 154, 1634.
Uneyama, H., et al. 1993. J. Biol. Chem. 268, 168.
Laurenza, A., et al. 1989. Trends Pharmacol. Sci. 10, 442.
Adashi, E.Y., and Resnick, C.E. 1986. J. Cell. Biochem. 31, 217.
Seamon, K.B., and Daly, J.W. 1986. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 20, 1.
Huang, R., et al. 1982. Cyclic Nucleotide Res. 8, 385.
Metzger, H., and Lindner, E. 1981. IRCS Med. Sci. Biochem. Cardiovasc. System Pharmacol. 9, 99.
Ficha técnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision01-February-2012 RFH
DescriptionThe major cell-permeable diterpene isolated from the Indian plant Coleus forskohlii. At low doses, it acts as a positive inotropic agent. At higher doses, it serves as a hypotensive and vasodilatory agent due to its actions as a smooth muscle relaxant. No major side effects are observed at effective doses. Forskolins pharmacological activities are due to its activation of adenylate cyclase (EC50 = 4 µM), resulting in increased cAMP levels. The exact mechanism of forskolins positive inotropic effect is unknown but may be related to a cAMP-dependent increase in Na+ permeability that results in indirect augmentation of Ca2+ release. Inhibits MAP kinase in rat renal mesangial cells (IC50 = 25 µM). Also acts as a Hh pathway antagonist. Shown to inhibit apoptosis in cerebellar granule cells and to induce apoptosis in resting human B lymphocytes.
FormLiquid
FormulationA 50 mM (5 mg/244 µl) solution of Forskolin, Coleus forskohlii (Cat. No. 344270) in DMSO.
Intert gas (Yes/No) Packaged under inert gas
Chemical formulaC₂₂H₃₄O₇
Structure formulaStructure formula
Purity≥97% by HPLC
Storage Protect from light
-20°C
Hygroscopic
Do Not Freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
Toxicity Irritant
ReferencesD'Orazio, J.A., et al. 2006. Nature 443, 340.
Noveen, A., et al. 1996. Biochem. Biophys. Res. Commun. 219, 180.
Galli, C., et al. 1995. J. Neurosci. 15, 1172.
Li, X., et al. 1995. Am. J. Physiol. 269, C986.
Lomo, J., et al. 1995. J. Immunol. 154, 1634.
Uneyama, H., et al. 1993. J. Biol. Chem. 268, 168.
Laurenza, A., et al. 1989. Trends Pharmacol. Sci. 10, 442.
Adashi, E.Y., and Resnick, C.E. 1986. J. Cell. Biochem. 31, 217.
Seamon, K.B., and Daly, J.W. 1986. Adv. Cyclic Nucleotide Protein Phosphorylation Res. 20, 1.
Huang, R., et al. 1982. Cyclic Nucleotide Res. 8, 385.
Metzger, H., and Lindner, E. 1981. IRCS Med. Sci. Biochem. Cardiovasc. System Pharmacol. 9, 99.